Genomic Medicine Guidance: A Point-of-Care App for Heritable Thoracic Aortic Diseases

1 Rohan Patil ^{+1*}, Fatima Ashraf ^{+2*}, Samer Abu Dayeh¹, Siddharth K. Prakash¹

- 2 †These authors contributed equally to this work.
- ³ ¹Department of Internal Medicine, McGovern Medical School, University of Texas Health Science
- 4 Center at Houston, Houston, Texas, USA
- ⁵ ²McWilliams School of Bioinformatics, University of Texas Health Science Center at Houston,
- 6 Houston, Texas, USA
- 7
- 8 Correspondence:
- 9 Siddharth K. Prakash, MD, PhD
- 10 McGovern Medical School
- 11 University of Texas Health Science Center at Houston
- 12 6431 Fannin Street, MSB 6.116, Houston, Texas 77030
- 13 <u>Siddharth.K.Prakash@uth.tmc.edu</u>
- 14 713-500-7003

Keywords: genomic medicine, point-of-care, thoracic aortic aneurysm, aortic dissection, decision support

10 decision suppor

17 Abstract

18 Genetic testing can determine familial and personal risks for heritable thoracic aortic aneurysms and

- 19 dissections (TAD). The 2022 ACC/AHA guidelines for TAD recommend management decisions
- 20 based on the specific gene mutation. However, many clinicians lack sufficient comfort or insight to
- 21 integrate genetic information into clinical practice. We therefore developed the Genomic Medicine
- 22 Guidance (GMG) app, an interactive point-of care tool to inform clinicians and patients about TAD
- 23 diagnosis, treatment, and surveillance. GMG is a REDCap-based app that combines publicly
- 24 available genetic data and clinical recommendations based on the TAD guidelines into one
- 25 translational education tool. TAD genetic information in GMG was sourced from the Montalcino
- Aortic Consortium, a worldwide collaboration of TAD centers of excellence, and the NIH genetic
- 27 repositories ClinVar and ClinGen. The app streamlines data on the 13 most frequently mutated TAD
 28 genes with 2,286 unique pathogenic mutations that cause TAD so that users receive comprehensive
- recommendations for diagnostic testing, imaging, surveillance, medical therapy, preventative surgical
- 30 repair, as well as guidance for exercise safety and management during pregnancy. The app output can
- 31 be displayed in a clinician view or exported as an informative pamphlet in a patient-friendly format.
- The overall goal of the GMG app is to make genomic medicine more accessible to clinicians and
- 33 patients, while serving as a unifying platform for research. We anticipate that these features will be
- 34 catalysts for collaborative projects that aim to understand the spectrum of genetic variants that
- 35 contribute to TAD.

36 1 Introduction

It is made available under a CC-BY-NC-ND 4.0 International license .

- 37 The global incidence of thoracic aortic dissections, 3 to 6 cases per 100,000 person-years, is almost
- 38 certainly underestimated because up to half of individuals who experience a dissection die before
- reaching a hospital (1). In 2022, 7% of out-of-hospital deaths were caused by acute aortic dissections.
- 40 In more than 20% of cases, a single genetic mutation that is frequently inherited can cause thoracic
- 41 aortic aneurysms or dissections (TAD, 2). Genetic testing for TAD can lead to earlier recognition of
- 42 patients who are at risk for acute aortic dissections and timely individualized interventions that can
- 43 prevent deaths. Technological advances have made genetic testing more practical for clinical use (3,
- 44 4). Gene-based management of TAD was codified in the recent ACC/AHA guidelines for aortic
- 45 disease, which provide different recommendations for diagnosis, surveillance, and preventative aortic
- 46 surgery depending on the mutated gene (5).
- 47 However, there are numerous barriers to implementing genetic information into routine clinical
- 48 workflows (2). Genetic counseling services are not readily accessible to clinicians or patients. Many
- 49 clinicians are not prepared to integrate genetic test results into clinical decision making. In a recent
- 50 survey, more than 75% of cardiovascular genetic tests were ordered by providers who do not have
- formal training in clinical genetics (6). Due to these gaps in care, patients frequently do not receive
- 52 appropriate pre- or post-test counseling to understand test results or adhere to guideline-based
- 53 recommendations (7).
- 54 Point of care tools synthesize complex medical information to guide clinical decision making (8). In
- 55 genomic medicine, point of care guidance can lead to more frequent and effective utilization of
- 56 genetic information in clinical practice (9, 10, 11). To address genomic medicine care gaps related to
- 57 TAD, we created Genomic Medicine Guidance (GMG), a point-of-care application that consolidates
- and clarifies evidence-based recommendations for clinical management of TAD based on genetic test
- results. Users who select a pathogenic mutation receive a comprehensive report that describes
- 60 associated clinical features and recommendations for diagnosis, surveillance, medical therapies, and
- 61 interventions. We illustrate how the features of the GMG app can lower barriers to integration of
- 62 genomic concepts into clinical practice and improve the recognition and treatment of TAD.

63 2 Materials and Methods

64 2.1 Project Design

- 65 The GMG app was implemented in a version of Research Electronic Data Capture (REDCap) that is
- 66 hosted at the McWilliams School of Biomedical Informatics at UTHealth Houston. REDCap is a
- 67 secure, web-based application designed to support data capture for research studies, providing 1) an
- 68 intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export
- 69 procedures; 3) automated export procedures for seamless data downloads to common statistical
- 70 packages; 4) procedures for importing data from external sources; and 5) a MySQL database server
- 71 to facilitate data queries and retrieval. Curated variant information and clinical recommendations are
- stored in the MySQL database. The user interface is implemented in PHP, a robust and widely used
- real scripting language. The database can be updated continuously by users who enter new variant data
- through the interface or by project managers who can upload bulk variant data using the data import
- 75 tools in REDCap.

76 **2.2** App Code

- 77 The GMG app is a custom PHP plugin that interacts with the REDCap framework to display, extract,
- add to, or modify the SQL database. The plugin sequentially queries the SQL database for gene and
- variant information or associated clinical content in response to user queries. The GMG plugin is

It is made available under a CC-BY-NC-ND 4.0 International license .

- 80 rendered in HTML, JavaScript (JS), and CSS. In particular, the app makes use of jQuery, a JS
- 81 library. When a user directly interfaces with the JS selection fields, AJAX methods in jQuery are
- 82 leveraged to dynamically load data in the background and update the display without reloading the
- 83 entire web page. AJAX methods make use of built-in PHP developer functions in REDCap to query
- 84 the database and return the appropriate information.
- 85 The tooltip class is used to display additional information about predefined terms such as acronyms
- 86 when the user hovers the mouse pointer over text. Results can be formatted for viewing on different
- 87 screens (phone, desktop, iPad) the Bootstrap v5.1.2 framework for CSS. We created download and
- 88 print functions by customizing a PHP script that retrieves data from the SQL database and converts
- 89 the data to PDF format using the dompdf package. The results file can be emailed to users using
- 90 built-in REDCap functions.

91 **3 Results**

92 **3.1 GMG Data Structure**

- 93 GMG data fields consist of the gene name, variant information, evidence for pathogenicity,
- 94 associated clinical features, gene-specific diagnostic workup, variant-specific diagnostic workup,
- 95 gene-specific surveillance, variant-specific surveillance, gene-specific medical therapy
- 96 recommendations, gene-specific aortic intervention thresholds, guidance during pregnancy, and
- 97 activity recommendations. New or revised data can be imported in a batch format using the REDCap
- 98 import tool (Supplemental Data).

99 3.2 GMG Genetic Content

- 100 The GMG app currently includes data on 2,270 pathogenic and likely pathogenic variants in 13 TAD
- 101 genes: ACTA2, PRKG1, TGFBR1, TGFBR2, SMAD3, MYLK, TGFB2, MYH11, FOXE3, LOX,
- 102 MFAP5, COL3A1, and FBN1 (Table 1).

103 3.3 User Workflow

- 104 Users may freely access GMG at https://go.uth.edu/GMG. To facilitate point of care queries, the 105 home page provides a prompt to select one HTAD gene and one variant from curated dropdown lists
- 106 (Figure 1). Users may view sample test report forms from commercial genetic laboratories with
- 107 highlighted variant information. After variant selection, users are required to verify the clinical
- features that prompted the genetic test and to attest that appropriate pre-test genetic counseling was
- 109 provided. If users enter a variant that is not on the curated list, the app interface provides an option
- 110 for them to upload the variant data and associated phenotypic information. The output tab describes
- 111 the selected variant, including evidence for pathogenicity in ClinVar, clinical features associated with
- the variant, including lifetime risks for aortic surgery or dissection, and evidence-based clinical
- recommendations for diagnostic and surveillance imaging of the aorta, medical therapy, and size
- 114 thresholds for elective aortic surgery. The recommendations are based on the 2022 ACC/AHA Aortic
- 115 Disease guidelines. The app displays clinician and patient-friendly outputs in different browser tabs
- 116 that can be printed, downloaded, or emailed in PDF format.

It is made available under a CC-BY-NC-ND 4.0 International license .



117

118 Figure 1. GMG app workflows. Users may select from a list of curated variants or enter a new variant

in one of 13 TAD genes. The app is available at https://go.uth.edu/GMG.

120 3.4 Researcher Workflow

121 Researchers can enter new data into the GMG app or update current app data using REDCap data

122 import tools. Batch genetic and clinical data for multiple gene variants can be uploaded

simultaneously into the GMG genotype-phenotype database using a single data import template

124 spreadsheet (Supplemental Data).

125 **3.5 Genetic Counseling Content**

126 GMG app users are required to verify that patients were appropriately selected for genetic testing and

127 received counseling about the benefits, risks, and implications of genetic testing. Users can also

128 access genetic counseling resources from within the app, including guidance to locate a genetic

129 counselor for telehealth consultation. Additional links to the Marfan Foundation and the Montalcino

130 Aortic Consortium, two advocacy groups with resources for newly diagnosed patients with TAD, are

131 provided on the output page.

132 **3.6 User Reviews**

133 Thirty-eight GMG users completed a Qualtrics feedback survey about their experiences with the app.

134 Users uniformly rated four components of the GMG app as very easy to use: the graphical interface

135 (85/100), selection of a curated gene variant (87/100), understanding clinical recommendations

136 (86/100), and entering a new clinical variant (89/100). Users also rated the clinical recommendations

137 as extremely helpful for clinical guidance (90/100) and highly likely to influence their clinical

138 practice (86/100). Users wrote that some genetic and clinical data in the app may be challenging for

139 individuals who do not have formal training in genetics. They also submitted design

recommendations to increase user engagement. Other suggestions included outreach to clinics and

141 professional organizations to establish a user network and an instructional video to orient new users.

142 **4 Discussion**

It is made available under a CC-BY-NC-ND 4.0 International license .

- 143 Thoracic aortic aneurysms predispose to deadly aortic dissections without obvious physical signs or
- symptoms and are frequently inherited as single gene mutations. Genetic testing for TAD can
- 145 identify affected relatives and save lives but is underutilized because genetic services are not
- 146 available to many families who are at risk. In this report, we describe a new point-of-care app, GMG,
- 147 that is intended to expand access to genetic information about genetic cardiovascular diseases
- including TAD. As reflected by user ratings, GMG simplifies the interpretation of genetic data for
- clinicians who do not have genetic expertise and provides valued clinical guidance based on the test
- 150 result.
- 151 Several recent studies and a review of 20 clinical decision support tools for genomic medicine
- 152 concluded that they improve risk assessment and lead to meaningful changes in clinical decisions
- 153 (9,11). Examples of such tools include an app that synthesizes data on somatic mutations in tumors to
- 154 target cancer therapies based on gene-specific prognosis (10). The Electronic Medical Records and
- 155 Genomics (eMERGE) network integrates contextual decision support into the electronic medical
- 156 record to streamline access to genetic testing (12).
- 157 GMG includes a genotype-phenotype database that will also promote collaborations by connecting
- 158 providers who enter similar genetic variants to resolve variants of uncertain significance or build case
- series to elucidate new disease phenotypes. Crowdsourcing through GMG will expand the clinical
- 160 and genetic content over time. Future versions of GMG will incorporate gene-based care guidance for
- 161 other adult-onset genetic cardiovascular diseases that are primarily managed by non-expert clinicians,
- 162 such as hyperlipidemias, cardiomyopathies, and channelopathies.

163 **5 Conclusions**

- 164 The GMG app expands access to genetic information in an era when most cardiovascular genetic
- tests are not supervised by genetic professionals. GMG will prevent deaths due to genetic
- 166 cardiovascular diseases by promoting evidence-based guidelines for gene-based decision making and
- 167 familial testing. The app also empowers patients to take an informed role in healthcare decisions.

168 6 Conflict of Interest

169 The authors declare that the research was conducted in the absence of any commercial or financial 170 relationships that could be construed as a potential conflict of interest.

171 **7** Author Contributions

- 172 RP: Data curation, Writing Original Draft; SA: Data curation; FA: Resources, Software, Writing –
 173 Review & Editing; SP: Conceptualization, Supervision, Funding acquisition, Writing Review &
 174 Editing
- 174 Editing.
- 175 **8 Funding**
- 176 This work was supported in part by UL1TR003167.

177 9 Acknowledgments

178 The authors are grateful to Dr. Elmer Bernstam for project oversight and support.

179 10 References

It is made available under a CC-BY-NC-ND 4.0 International license .

- Zhou, Z., Cecchi, A. C., Prakash, S. K., & Milewicz, D. M. (2022). Risk Factors for Thoracic Aortic Dissection. *Genes*, 13(10), 1814–. https://doi.org/10.3390/genes13101814
- Musunuru, K., Hershberger, R. E., Day, S. M., Klinedinst, N. J., Landstrom, A. P., Parikh, V.
 N., Prakash, S., Semsarian, C., & Sturm, A. C. (2020). Genetic Testing for Inherited
 Cardiovascular Diseases: A Scientific Statement From the American Heart Association.
- 185 *Circulation. Genomic and Precision Medicine*, 13(4), e000067–e000067
- Robin, N., Tabereaux, P., Benza, R., Korf, B. (2007). Genetic Testing in Cardiovascular
 Disease. *J Am Coll Cardiol*, Aug, 50 (8) 727–737.
- Halbisen, A. L., & Lu, C. Y. (2023). Trends in Availability of Genetic Tests in the United States, 2012-2022. *Journal of personalized medicine*, 13(4), 638. https://doi.org/10.3390/jpm13040638
- Isselbacher, E. M., Preventza, O., Black III, J. H., Augoustides, J. G., Beck, A. W., Bolen, M.
 A., Braverman, A. C., Bray, B. E., Brown-Zimmerman, M. M., Chen, E. P., Collins, T. J.,
 DeAnda, J., Fanola, C. L., Girardi, L. N., Hicks, C. W., Hui, D. S., Schuyler Jones, W.,
 Kalahasti, V., Kim, K. M., ... Woo, Y. J. (2022). 2022 ACC/AHA Guideline for the Diagnosis
- Kalahasti, V., Kim, K. M., ... Woo, Y. J. (2022). 2022 ACC/AHA Guideline for the Diagnosis
 and Management of Aortic Disease: A Report of the American Heart Association/American
 College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation (New York, N.Y.)*, 146(24), e334–e482. https://doi.org/10.1161/CIR.000000000001106
- Lopez Santibanez Jacome, L., Dellefave-Castillo, L. M., Wicklund, C. A., Scherr, C. L.,
 Duquette, D., Webster, G., Smith, M. E., Kalke, K., Gordon, A. S., De Berg, K., McNally, E.
 M., & Rasmussen-Torvik, L. J. (2022). Practitioners' Confidence and Desires for Education in
 Cardiovascular and Sudden Cardiac Death Genetics. *Journal of the American Heart Association*, 11(7), e023763–e023763. https://doi.org/10.1161/JAHA.121.023763
- 203
 7. Samuel, G. N., Dheensa, S., Farsides, B. Fenwick, A., & Lucassen, A. (2017). Healthcare
 204 professionals' and patients' perspectives on consent to clinical genetic testing: moving towards
 205 a more relational approach, *BMC Med Ethics*. 18(47).
- 8. Ketchum, A. M., Saleh, A. A., & Jeong, K. (2011). Type of evidence behind point-of-care clinical information products: a bibliometric analysis. *Journal of medical Internet research*, *13*(1), e21. https://doi.org/10.2196/jmir.1539
- Sebastian, A., Carroll, J. C., Oldfield, L. E., Mighton, C., Shickh, S., Uleryk, E., & Bombard,
 Y. (2021). Effect of genetics clinical decision support tools on health-care providers' decision
 making: a mixed-methods systematic review. *Genetics in Medicine*, 23(4), 593–602.
 https://doi.org/10.1038/s41436-020-01045-1
- Manolio, T. A., Chisholm, R. L., Ozenberger, B., Roden, D. M., Williams, M. S., Wilson, R.,
 Bick, D., Bottinger, E. P., Brilliant, M. H., Eng, C., Frazer, K. A., Korf, B., Ledbetter, D. H.,
 Lupski, J. R., Marsh, C., Mrazek, D., Murray, M. F., O'Donnell, P. H., Rader, D. J., ...
 Ginsburg, G. S. (2013). Implementing genomic medicine in the clinic: the future is here.
- 217 Genetics in Medicine, 15(4), 258–267. https://doi.org/10.1038/gim.2012.157
- Way, H., Williams, G., Hausman-Cohen, S., & Reeder, J. (2021). Genomics as a Clinical
 Decision Support Tool: Successful Proof of Concept for Improved ASD Outcomes. *Journal of Personalized Medicine*, 11(7), 596–. https://doi.org/10.3390/jpm11070596
- 12. McCarty, Catherine A et al. "The EMERGE Network: A Consortium of Biorepositories Linked to Electronic Medical Records Data for Conducting Genomic Studies." *BMC genomics* 4.1 (2011): 13–13. Web.